drugset / Trial / NCT06020352

The Efficacy and Safety of KN046 Combined With Axitinib

NCT06020352

Phase 2/3 Unknown 20 enrolled Shanghai Pulmonary Hospital, Shanghai, China
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the efficacy of KN046 combined with acitinib as a neoadjuvant therapy for resectable NSCLC through primary pathological response rate and surgical resection rate

Timeline

Start
2023-08-25
Primary completion
2025-07-01
Completion
2025-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule
Subject ERFONRILIMAB Monoclonal antibody